Physician profile
Todd Simon
NPI 1225073489
$5,112.63
in general payments reported to CMS, 2019-2025
30 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $348 · 2021: $585 · 2022: $733 · 2023: $771 · 2024: $873 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,727.20 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.95 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $410.82 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $325.65 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $269.97 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Gilead Sciences, INC. | $201.43 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $186.50 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $148.14 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $144.27 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $122.61 | 2022-2023 | |
| Lilly USA, LLC | $116.76 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $102.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $87.17 | 2019-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $85.80 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $78.13 | 2024-2025 | Vegzelma |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $59.58 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $52.67 | 2023-2024 | Linzess |
| Redhill Biopharma INC. | $51.61 | 2020-2022 | |
| Pfizer INC. | $51.42 | 2019-2025 | |
| Novo Nordisk INC | $48.62 | 2025 | Wegovy |
| Ardelyx, INC. | $41.14 | 2023-2025 | Ibsrela |
| Allergan, INC. | $39.01 | 2019 | |
| Genzyme Corporation | $35.34 | 2025 | |
| Aimmune Therapeutics, INC. | $24.41 | 2025 | Vowst |
| Daiichi Sankyo INC. | $20.07 | 2024 | Injectafer |
| Medtronic, INC. | $19.57 | 2022 | |
| Ucb, INC. | $19.02 | 2019 | |
| Merck Sharp & Dohme LLC | $15.84 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $15.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,608.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.